← Back to Home

EIT Pharma

Private
#Hepatitis#Liver Disease#Antiviral

Biopharmaceutical company developing lonafarnib for chronic hepatitis delta (HDV), a serious liver infection. NDA accepted by FDA in 2026.

Company Info

Sector:Antiviral Therapeutics
Headquarters:USA
Founded:2020
Website:www.eitpharma.com/

Upcoming Milestones & Key Dates

2026/2027
Regulatory

PDUFA date for lonafarnib NDA

Clinical Development Pipeline

Lonafarnib

Target: Farnesyltransferase inhibitor
Chronic hepatitis delta (HDV)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Careers & Job Openings

See all open roles

Apply Now →